Nevertheless, the limited single-agent clinical efficacy of the mTOR inhibitor everolimus [83], as well as of the mTOR and PI3K inhibitor samotolisib [85], highlights once again the presence of an extensive crosstalk between the different signaling intracellular pathways promoting cancer cell growth and survival. This evidence concerns the gene MTOR and cancer.